psychedelics to quickly mushroom beyond what is safe. While offlabel use may be a useful way to provide access to promising treatments, it must be done responsibly and with an eye toward future evidence-based advancements in medical science; regulators, policy makers, and health authorities must carefully examine and create guardrails for the promotion and off-label use of psychedelics.

Aim To report incidence, demographic and clinical characteristics, and symptom outcome of functional neurological disorder (FND) in children. Method Children diagnosed with FND at a regional children's hospital were prospectively recruited by weekly active surveillance for 36 months. Demographic, clinical, and follow‐up data were retrospectively extracted by review of electronic records. Descriptive statistical analyses were used. Results Ninety‐seven children (age range 5–15 years) met the case definition of FND (annual incidence 18.3 per 100 000 children). Children with FND were likely to be female (n = 68 [70%]) and older (median 13 years) with no difference in the Scottish Index of Multiple Deprivation (marker of socioeconomic status) compared with the general childhood population. Functional motor (41%) and sensory (41%) symptoms were most common; other somatic symptoms such as headache (31%) and pain (27%) were frequent. Self‐reported psychiatric symptoms and infection/inflammation were the most common predisposing and precipitating factors respectively. At a median of 15 months follow‐up, 49% of 75 children reported improvement or resolution of FND symptoms with no prognostic factors found. Interpretation At this regional centre, FND in children had a higher incidence than previously reported and a less optimistic outcome than in some other studies.